Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs-Reference-Cited by-同舟云学术

Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs

Published:2019-10 Issue:4 Volume:71 Page:666-672
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Llaneras Jordi,Riveiro-Barciela Mar,Lens Sabela,Diago Moisés,Cachero Alba,García-Samaniego Javier,Conde Isabel,Arencibia Ana,Arenas Juan,Gea Francisco,Torras Xavier,Luis Calleja José,Antonio Carrión José,Fernández Inmaculada,María Morillas Rosa,Rosales José Miguel,Carmona Isabel,Fernández-Rodríguez Conrado,Hernández-Guerra Manuel,Llerena Susana,Bernal Vanesa,Turnes Juan,González-Santiago Jesús M.,Montoliu Silvia,Figueruela Blanca,Badia Ester,Delgado Manuel,Fernández-Bermejo Miguel,Iñarrairaegui Mercedes,Pascasio Juan Manuel,Esteban Rafael,Mariño Zoe,Buti Maria

Publisher

Elsevier BV

Subject

Hepatology

Reference33 articles.

1. Oral combination therapies for hepatitis C virus infection: successes, challenges, and unmet needs;Naggie;Annu Rev Med,2017

2. EASL Recommendations on Treatment of Hepatitis C 2018. Journal of hepatology. 2018;69:461–511.

3. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology (Baltimore, Md). 2015;62(3):932–954.

4. Hepatitis C Guidance 2018 Update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis. 2018;67(10):1477–1492.

5. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis;Curry;N Engl J Med,2015

Cited by 78 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hepatitis C Virus: History and Current Knowledge;Gastroenterology Insights;2024-08-08

2. Rare HCV subtypes and retreatment outcomes in a cohort of European DAA-experienced patients;JHEP Reports;2024-07

3. Synthetic Methods of Quinoxaline Derivatives and their Potential Anti-inflammatory Properties;Mini-Reviews in Medicinal Chemistry;2024-06-20

4. ‘Unusual’ HCV genotype subtypes: origin, distribution, sensitivity to direct-acting antiviral drugs and behaviour on antiviral treatment and retreatment;Gut;2024-05-23

5. Real‐life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir;Alimentary Pharmacology & Therapeutics;2024-05-02